Data gathered: August 2
AI Stock Analysis - Castle Biosciences (CSTL)
Analysis generated May 2, 2025. Powered by Chat GPT.
Castle Biosciences is a molecular diagnostics company offering tests to improve treatment outcomes for patients with dermatological cancers and other difficult-to-diagnose conditions. The company leverages innovative genomic technology to provide actionable insights that help clinicians make more informed therapeutic decisions. These insights are pivotal for personalized medicine, aiming at enhancing patient care and optimizing clinical resources.
Stock Alerts - Castle Biosciences (CSTL)
 |
Castle Biosciences | July 17 Price is down by -7.1% in the last 24h. |
|
Castle Biosciences | July 2 Insider Alert: MAETZOLD DEREK J is selling shares |
|
Castle Biosciences | June 17 Business Outlook among employees is down by 4.2% over the last month. |
|
Castle Biosciences | June 10 Employee Rating is up by 2.6% over the last month. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Castle Biosciences
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 6 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 17,000 | Sign up | Sign up | Sign up |
| Employee Rating | 78 | Sign up | Sign up | Sign up |
| Google Trends | 29 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 29 | Sign up | Sign up | Sign up |
| Facebook Followers | 749 | Sign up | Sign up | Sign up |
| Instagram Followers | 1,212 | Sign up | Sign up | Sign up |
| Reddit Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 3 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 988 | Sign up | Sign up | Sign up |
| Twitter Followers | 743 | Sign up | Sign up | Sign up |
| Twitter Mentions | 9 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 544 | Sign up | Sign up | Sign up |
| News Mentions | 1 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 71 | Sign up | Sign up | Sign up |
| Linkedin Employees | 621 | Sign up | Sign up | Sign up |
About Castle Biosciences
Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions.
| Price | $14.65 |
| Target Price | Sign up |
| Volume | 421,590 |
| Market Cap | $437M |
| Year Range | $14.65 - $32.72 |
| Dividend Yield | 0% |
| PE Ratio | 31.21 |
| Analyst Rating | 100% buy |
| Earnings Date | August 4 '25 |
| Industry | Biotechnology |
In the news
 |
Castle Biosciences (CSTL) Projected to Post Quarterly Earnings on MondayAugust 1 - ETF Daily News |
|
Envestnet Asset Management Inc. Has $1.40 Million Stock Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL)August 1 - ETF Daily News |
|
GSA Capital Partners LLP Sells 3,658 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL)July 31 - ETF Daily News |
Castle Biosciences to Present at the Canaccord Genuity 45th Annual Growth ConferenceJuly 29 - GlobeNewswire |
|
 |
Earnings Preview: Castle Biosciences, Inc. (CSTL) Q2 Earnings Expected to DeclineJuly 28 - Yahoo |
|
Cerity Partners LLC Invests $423,000 in Castle Biosciences, Inc. (NASDAQ:CSTL)July 27 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '25 | 88M | 16M | 88M | -26M | 0 | -0.904 |
| Q4 '24 | 86M | 16M | 70M | 9.6M | 14M | 0.320 |
| Q3 '24 | 86M | 16M | 70M | 2.3M | 12M | 0.080 |
| Q2 '24 | 87M | 17M | 70M | 8.9M | 12M | 0.310 |
| Q1 '24 | 73M | 17M | 56M | -2.5M | 870,000 | -0.090 |
Insider Transactions View All
| MAETZOLD DEREK J filed to sell 3,615 shares at $20.3. July 1 '25 |
| MAETZOLD DEREK J filed to sell 69,683 shares at $20.3. July 1 '25 |
| MAETZOLD DEREK J filed to sell 44,986 shares at $20.3. July 1 '25 |
| MAETZOLD DEREK J filed to sell 52,923 shares at $20.3. July 1 '25 |
| MAETZOLD DEREK J filed to sell 4,275 shares at $21.5. April 23 '25 |
Similar companies
Read more about Castle Biosciences (CSTL) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Castle Biosciences?
The Market Cap of Castle Biosciences is $437M.
What is Castle Biosciences' PE Ratio?
As of today, Castle Biosciences' PE (Price to Earnings) ratio is 31.21.
When does Castle Biosciences report earnings?
Castle Biosciences will report its next earnings on August 4 '25.
What is the current stock price of Castle Biosciences?
Currently, the price of one share of Castle Biosciences stock is $14.65.
How can I analyze the CSTL stock price chart for investment decisions?
The CSTL stock price chart above provides a comprehensive visual representation of Castle Biosciences' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Castle Biosciences shares. Our platform offers an up-to-date CSTL stock price chart, along with technical data analysis and alternative data insights.
Does CSTL offer dividends to its shareholders?
As of our latest update, Castle Biosciences (CSTL) does not offer dividends to its shareholders. Investors interested in Castle Biosciences should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Castle Biosciences?
Some of the similar stocks of Castle Biosciences are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.